|Home | About | Journals | Submit | Contact Us | Français|
Development of mice expressing either ovine (Tg338) or cervid (TgElk) prion protein (PrP) have aided in characterization of scrapie and chronic wasting disease (CWD), respectively. Experimental inoculation of sheep with CWD prions has demonstrated the potential for interspecies transmission but, infection with CWD versus classical scrapie prions may be difficult to differentiate using validated diagnostic platforms. In this study, mouse bioassay in Tg338 and TgElk was utilized to evaluate transmission of CWD versus scrapie prions from small ruminants. Mice (≥5 per homogenate) were inoculated with brain homogenates from clinically affected sheep or goats with naturally acquired classical scrapie, white-tailed deer with naturally acquired CWD (WTD-CWD) or sheep with experimentally acquired CWD derived from elk (sheep-passaged-CWD). Survival time (time to clinical disease) and attack rates (brain accumulation of protease resistant PrP, PrPres) were determined. Inoculation with classical scrapie prions resulted in clinical disease and 100% attack rates in Tg338, but no clinical disease at endpoint (>300days post-inoculation, p.i.) and low attack rates (6.8%) in TgElk. Inoculation with WTD-CWD prions yielded no clinical disease or brain PrPres accumulation in Tg338 at endpoint (>500 days p.i.), but rapid onset of clinical disease (~121 days p.i.) and 100% attack rate in TgElk. Sheep-passaged-CWD resulted in transmission to both mouse lines with 100% attack rates at endpoint in Tg338 and an attack rate of ~73% in TgElk with some culled due to clinical disease. These primary transmission observations demonstrate the potential of bioassay in Tg338 and TgElk to help differentiate possible infection with CWD versus classical scrapie prions in sheep and goats.
Classical scrapie is a naturally occurring transmissible spongiform encephalopathy (TSE) of sheep and goats. Though it has been recognized in some regions of the world for over 250 years (reviewed by Schneider et al., 2008), classical scrapie (herein just ‘scrapie’) was first diagnosed in the USA in 1947 following the import of an infected sheep. In contrast, chronic wasting disease (CWD) is a naturally occurring TSE of cervids (elk, deer and moose) which was first observed in the 1960s in deer held captive in several wildlife facilities in the USA (Williams & Young, 1980; reviewed by Haley & Hoover, 2015). Both scrapie and CWD are transmissible, infectious, neurodegenerative diseases for which there are no treatments. Prions, the novel proteinaceous infectious particles that are believed to be the causative agent of TSEs, induce misfolding of normal cellular prion protein (PrPC) to a form that is relatively resistant to protease cleavage (PrPres) (Prusiner, 1982; review by Ryou, 2007). Misfolded PrP associated with scrapie disease is often abbreviated PrPSc, whereas in CWD, the misfolded protein may be abbreviated PrPCWD. A hallmark of prion diseases is the slow, progressive development of central neuropathology that is accompanied by accumulation of misfolded PrP. After a variably long incubation period, clinical disease often manifests as pruritus, ataxia, weight loss, tremors and changes in behaviour (review by Haley & Hoover, 2015; Konold & Phelan, 2014), but ultimately leads to the demise of the animal.
Animal bioassay is a gold standard technique for the recognition and characterization of different prion types (Beck et al., 2012b; Bruce et al., 2002; Thackray et al., 2012). The use of wild-type inbred strains of mice (e.g. RIII, C57BL and VM) has aided in differentiating types of scrapie prions as measured by incubation and survival times, histopathologic lesion profiles, brain accumulation profiles of PrPSc and biochemical characterization of PrPres (Beck et al., 2010, 2012a, b; Bruce et al., 2002, 2003; Vulin et al., 2012). In contrast, there have been few observations of CWD transmission to wild-type mice (Lee et al., 2013). To reduce incubation times and number of subpassages for studies of scrapie prions and improve transmission efficiency of CWD prions, transgenic mice were developed to express the ovine or cervid prion protein gene (PRNP), respectively (Browning et al., 2004; Cordier et al., 2006; Crozet et al., 2001; LaFauci et al., 2006; Tamgüney et al., 2006; Vilotte et al., 2001). Using transgenic mice expressing ovine PRNP (ovinized mice), scrapie incubation times were substantially reduced compared with incubation times in wild-type mice (Crozet et al., 2001; Vilotte et al., 2001) while histopathologic profiles and PrPres biochemical features characteristic of scrapie prion types were maintained (Baron et al., 2004; Chong et al., 2015; Cordier et al., 2006). In addition, ovinized mice have been shown to be permissive to scrapie prions derived from goats with naturally acquired disease (O'Rourke et al., 2012). Several transgenic mouse lines expressing cervid PRNP (cervidized mice) have been generated for studies of CWD prions. Cervidized mice have shown reduced incubation times with increased attack rates compared with wild-type mice (Lee et al., 2013) and have proven useful in the discrimination of CWD prion types isolated from different species [mule deer versus white-tailed deer (WTD) versus elk] (Browning et al., 2004; LaFauci et al., 2006; Tamgüney et al., 2006). Thus, ovinized and cervidized mice have been established as appropriate mouse bioassay models for the study of scrapie and CWD prions, respectively.
As countries work diligently to eradicate scrapie in sheep and goats, it is important to develop tools that differentiate disease resulting from novel versus known sources of prions in an effort to identify TSE reservoirs that could lead to disease re-emergence, especially in regions where other TSEs naturally exist. A potentially novel source to small ruminants would be from natural exposure to CWD prions. CWD continues to increase in both prevalence and geographic distribution in North America (reviewed by Haley & Hoover, 2015); the longest known presence in the USA is in the states of CO and WY (Williams & Young, 1980). Sheep are susceptible to CWD prions when inoculated intracerebrally with brain homogenate from mule deer with CWD, but the attack rate is low and PRNP genotype of the recipient sheep may contribute to susceptibility (Hamir et al., 2006). It is currently unknown if sheep naturally exposed to CWD prions will readily become infected or if the resulting TSE would appear different (clinically and/or diagnostically) from classical scrapie in sheep and goats. Transgenic mice have been used to examine the potential for TSEs to cross the species barrier (Beck et al., 2012a; Tamgüney et al., 2006). This study evaluates primary transmission of scrapie prions from goats or sheep and CWD prions from WTD to both cervidized and ovinized transgenic mice (TgElk and Tg338, respectively). Furthermore, mouse bioassay is used to assess transmission of CWD prions to these mice following primary experimental passage through sheep.
Brain homogenates from goats (G3538, G3558, G3953 and G30-75), sheep (S3178) and WTD (WTD804) with naturally acquired TSEs (scrapie in goats and sheep; CWD in deer) were assessed for variation in PrPres molecular mass and glycoform ratios by Western blotting. As expected, some animal-to-animal variation was observed. Molecular mass of unglycosylated PrPres (lowest band, Fig. 1a) from WTD804 was ~0.5 kDa larger (P<0.05) than PrPres from G3538 and G3558, but not PrPres from G3953, G30-75 or S3178. Unglycosylated PrPres from brains of sheep (CFIA113 and CFIA122) experimentally inoculated with a pooled homogenate of brain and lymph node from elk with CWD was ~1kDa smaller (P<0.05) compared with PrPres from all animals with naturally acquired scrapie or CWD. Molecular mass of unglycosylated PrPres was also compared between the experimentally inoculated sheep and the pooled elk homogenate (CFIA Elk) the sheep were inoculated with. Unglycosylated PrPres from CFIA113 and CFIA122 was ~1.75kDa smaller (P<0.05) than PrPres from CFIA Elk. The molecular mass of unglycosylated PrPres from CFIA Elk was also ~0.75kDa larger (P<0.05) than PrPres from goats with naturally acquired scrapie, but not significantly different from PrPres in the sheep or WTD homogenates tested. Using a three-axis plot to visualize glycoform ratios, diglycosylated PrPres appeared to be the most abundant, and unglycosylated PrPres the least abundant in all homogenates (Fig. 1b).
The relative level of misfolded PrP in each donor brain homogenate used for mouse inoculations was assessed by enzyme immunoassay (EIA) and expressed as the equivalent starting wet tissue weight of the endpoint serial dilution. Levels of misfolded PrP were similar for inocula prepared from donor animals G3953, WTD804 and CFIA113 with each at ~6µg starting wet tissue weight. The last serial dilution that yielded a detectable EIA signal was equivalent to approximately 94µg for CFIA122. The relative levels of misfolded PrP in the inocula from other donors were similarly determined and previously reported as follows (O'Rourke et al., 2012): ~23µg starting wet tissue weight for G3558, 46µg for G3538, 93µg for G30-75 and 186µg for S3178.
Transgenic mice expressing ovine PRNP (Tg338) or cervid PRNP (TgElk) underwent intracerebral inoculation with brain homogenate from goats or a sheep with naturally acquired scrapie (G3538, G3558, G3953, G30-75 or S3178) and were monitored for the development of clinical signs associated with TSE disease (Bruce et al., 2004). Mice were culled at clinical disease, for intercurrent disease, or within an endpoint period chosen to limit the occurrence of common age-related health issues (e.g. penile prolapse and chronic conjunctivitis). The endpoint period for Tg338 mice was 500–600days post-inoculation (p.i.). In comparison to Tg338 mice, TgElk mice are short-lived and required an endpoint cull period of 300–375days p.i. TgElk mice also demonstrate hyperexcitability at baseline; thus, this behaviour was not considered a clinical sign of TSE disease in this line of mice.
Tg338 mice inoculated with scrapie prions were culled with clinical signs such as ataxia, extreme lethargy, weight loss, hunched stance or gait, tremors, clenched paws or hyperexcitability. The onset of clinical disease and attack rates for Tg338 mice are shown in Fig. 2(a), and outcomes are summarized in Table 1. Most mice were culled between 143 and 300days p.i. with additional mice culled at 331, 373 (both in G3538 group) and 421days p.i. (S3178 group). The accumulation of PrPres in the brain was assessed in Tg338 by Western blot (WB) analysis to determine attack rates (Table 1). All Tg338 mice culled due to clinical disease were positive for PrPres in the brain (see representative WBs in Fig. 3) as was a mouse culled due to intercurrent health issues at an earlier time point (69days p.i.). The molecular mass of PrPres from Tg338 inoculated with classical scrapie prions showed a small reduction (1–2kDa) compared with the original inoculum. This reduction was previously demonstrated with mouse bioassay of brain homogenate from S3178, G3538, G3558 and G30-75 (O'Rourke et al., 2012), and was found to be due to an altered proteinase K (PK) cleavage site in PrPres that accumulates in the brain of inoculated Tg338 as compared to that present in the original sheep inoculum.
The onset of clinical disease and attack rates in TgElk mice inoculated with brain homogenate from goats or sheep with naturally acquired classical scrapie are shown in Fig. 2(b) and outcomes summarized in Table 1. Clinical signs associated with the onset of TSE disease were not observed before the assay endpoint. All TgElk mice were assessed for brain PrPres accumulation to determine attack rates in the absence of clinical signs (see representative WBs in Fig. 3). Brain PrPres was detected in 3 of 44 mice; the positive mouse culled at 315days p.i. was inoculated with brain homogenate from G30-75, whereas two mice culled at 339days p.i. were inoculated with brain homogenate from G3953. Thus, classical scrapie prions transmitted efficiently to Tg338 with near 100% onset of clinical disease and 100% attack rates. However, transmission was inefficient in TgElk with no onset of clinical disease prior to the endpoint period and low (~6.8%) attack rates.
Concurrent with inoculation of scrapie prions, Tg338 and TgElk mice underwent intracerebral inoculation with a pooled brain homogenate from WTD with naturally acquired CWD (WTD804). The onset of clinical disease and attack rates in mice are shown in Fig. 4 and outcomes summarized in Table 2. Tg338 mice inoculated with WTD804 did not demonstrate clinical signs associated with TSE disease. Mice were culled either in the endpoint period or due to intercurrent health issues; brain PrPres accumulation was not detected (see representative WB in Fig. 3). Inoculation of TgElk with WTD804 resulted in the onset of clinical disease. Mice displayed clinical signs such as ataxia, extreme lethargy, weight loss, hunched stance or gait, circling, tail or hind-end mutilation of self or others and extreme obesity to the point of inhibiting movement. All TgElk inoculated with WTD804 were culled by 128days p.i. and were positive for PrPres in the brain (see representative WB in Fig. 3). Thus, CWD prions were transmitted efficiently to TgElk mice with no evidence of transmission to Tg338.
To evaluate if transmission of CWD prions was altered following primary passage through sheep, brain homogenates from sheep experimentally inoculated with CWD (CFIA113 and CFIA122) were used to inoculate Tg338 and TgElk mice. The onset of clinical disease and attack rates are shown in Fig. 5 and outcomes are summarized in Table 2. Although Tg338 inoculated with CFIA113 or CFIA122 were non-clinical when culled in the endpoint period, all mice were positive for PrPres in the brain (100% attack rate; see representative WBs in Fig. 3). Clinical disease was observed near the endpoint period in some TgElk inoculated with CFIA113 or CFIA122. The accumulation of PrPres in the brain was detected in all TgElk that were culled with clinical signs or due to intercurrent health issues in addition to suspected clinical disease. One additional, non-clinical TgElk in each inoculation group was positive for brain PrPres, but only when the mouse brain homogenate was first enriched using phosphotungstic acid precipitation (PTA-WB), see Methods for details. Thus, CWD prions following primary passage in sheep transmitted efficiently to both Tg338 and TgElk with 100 and 72.7% attack rates, respectively.
There are currently no known cases of interspecies transmission of CWD prions to sheep or goats through natural exposure, and transmission resulting from direct inoculation has been relatively inefficient. Nevertheless, the potential for natural exposure of sheep and goats to CWD prions is presumably rising in parallel with the increasing incidence and geographic range of CWD occurring in both free-ranging and farmed cervids in North America (review by Haley & Hoover, 2015). Should interspecies transmission of CWD occur naturally, the ability to differentiate CWD versus scrapie infection in sheep and goats may enhance epidemiological investigations and surveillance efforts attempting to identify novel sources of prion exposure. This study assessed transmission of classical scrapie and CWD prions from their native hosts to transgenic mouse lines expressing the ovine or cervid PrP. Inoculation of transgenic mice with scrapie prions from goats or sheep or CWD prions from WTD resulted in distinct transmission patterns. Scrapie prions transmitted efficiently to Tg338 but not TgElk, whereas CWD prions from a natural host efficiently transmitted to TgElk but not Tg338. Unlike these distinct transmission patterns, efficient transmission of CWD prions following primary passage in sheep was observed in both Tg338 and TgElk mice.
Experimentally transmitted CWD in small ruminants has been difficult to distinguish from natural cases of classical scrapie. In sheep, intracerebral inoculation of CWD prions from mule deer resulted in immunohistochemistry-detected brain and tonsil accumulation patterns and PrPres molecular profiles that were very similar to those observed in classical scrapie (Hamir et al., 2006). In the current study, small variations in molecular mass of brain homogenate PrPres were detected among species (Fig. 1), but the variation observed in those tested did not segregate infection with scrapie versus CWD prions. This agrees with previous reports of variation in PrPres molecular mass (Stack et al., 2004) and no significant variation in glycoform ratios (Race et al., 2002). Further, PrPres from sheep inoculated with elk CWD prions (sheep-passaged-CWD) was significantly different from both scrapie- and CWD-associated PrPres from their native hosts. While these shifts in PrPres molecular mass occur upon primary interspecies transmission, they are likely too small as compared to natural variation of scrapie PrPres to allow robust differentiation of prion type. Thus, consistent with the conclusion of Hamir et al. (2006), standard methods will detect, but are not likely to differentiate, primary infections of sheep or goats with CWD prions versus scrapie prions.
The use of Tg338 and TgElk mouse lines is well established in the respective study of scrapie and CWD (Beck et al., 2013; Jeon et al., 2013; LaFauci et al., 2006; Langevin et al., 2011; O'Rourke et al., 2012; Thackray et al., 2011a, b; Tixador et al., 2010; Vilotte et al., 2001). Such studies include the use of Tg338 mice to differentiate strains of classical scrapie prions within sheep (Thackray et al., 2008), to detect mixed infection of sheep with classical and atypical scrapie prions (Chong et al., 2015) and to show the similar transmission phenotypes of classical scrapie prion isolates from sheep and goats (O'Rourke et al., 2012). Similar studies have used cervidized mice, including TgElk, to examine the phenotypes of CWD prions isolated from cervid species (Browning et al., 2004; Duque Velasquez et al., 2015; LaFauci et al., 2006). Few studies have used ovinized and cervidized mice to model interspecies infection of CWD and scrapie. Tg338 intracerebrally inoculated with elk CWD prions resulted in low transmission rates observed in the brain but high transmission rates observed in the spleen suggesting that cross-species transmission could preferentially accumulate in peripheral lymphoid tissues (Béringue et al., 2012). Tamgüney and colleagues found no evidence of CWD transmission to Tg338 mice using inocula derived from WTD, elk or mule deer (Tamgüney et al., 2006) or to a different ovinized mouse using inoculum from WTD (Tamgüney et al., 2009). A similar lack of detectable transmission was observed in brains of Tg338 inoculated with WTD804 in the current study (Fig. 4, Table 2). Studies evaluating susceptibility of cervidized mice to scrapie are also limited. Browning et al. (2004) did not observe transmission of mouse-adapted scrapie (RML strain) into one cervidized mouse line. Using a different cervidized mouse line, Tamgüney and colleagues observed transmission of RML scrapie and a European strain of scrapie serially passaged in sheep (SSBP/1), but not a natural scrapie isolate from a North American sheep (Tamgüney et al., 2009). In the current study, a low overall attack rate (~6.8%) was observed in TgElk inoculated with scrapie prions derived from clinical cases in North America. The evidence of transmission to TgElk, albeit low, could be due to the use of a different cervidized mouse than what was used in previous studies by others. Another possible contributing factor to the low attack rates could be that the homogenates resulting in TgElk brain PrPres accumulation were from goats. Future studies with additional goats and sheep with scrapie will be necessary to evaluate whether prion transmission from cervids to goats, although limited, may be more efficient than cervids to sheep.
Transmission of CWD from mule deer or elk to sheep has been achieved following intracerebral inoculation (Hamir et al., 2006; Mitchell et al., 2015). Yet, inoculation with brain homogenate from WTD with CWD did not result in brain accumulation of PrPres during primary passage in ovinized mice (Tg338). One factor that may have contributed to the lack of transmission could be varying levels of PrPSc and PrPCWD between brain homogenates from animals with scrapie and CWD, respectively. Laboratory biochemical assays such as WB or EIA do not correlate with infectious titres, but it has been shown that brain homogenates with higher prion levels as detected by EIA tend to also have higher infectious titres in mouse bioassay (Gonzalez et al., 2012). All homogenates used in this study were prepared from cases with clinical disease at the time of cull. While a complete titration for infectivity by mouse bioassay was not performed with these samples, varying levels of PrPSc and PrPCWD were detected by EIA of an endpoint dilution series for each homogenate. Several homogenates (G3953, WTD804 and CFIA113) demonstrated high PrPSc or CWD levels relative to the others by EIA, yet infectivity was primarily observed with G3953 in Tg338 (100% attack rate at 143–146 days p.i.) and with WTD804 in TgElk (100% attack rate at 113–128 days p.i.). Interestingly, CWD prions after primary passage through sheep (CFIA113) that appeared to have high PrPCWD levels by EIA transmitted to both Tg338 and TgElk with near 100% attack rates but cull was near or in the endpoint period. Although EIA suggests there are similar levels of PrPSc and PrPCWD in these three homogenates, infectious titre or other donor or recipient mouse factors may have contributed to the variation in transmission that was observed. One factor known to contribute to scrapie transmission is PRNP genotype. All sheep used in the current study were of a scrapie-susceptible genotype (alanine at codon 136 and glutamine at codon 171), whereas the goats represented several different PRNP genotypes (previously described in O'Rourke et al., 2011, 2012). There was no clear association between donor PRNP genotype and transmission to Tg338 or TgElk mice. It is unknown if genotype plays a role in susceptibility of sheep and goats to CWD prions, but observations by Hamir and colleagues suggest that it may (Hamir et al., 2006). Additional studies will be needed to fully determine the role of PRNP genotype in the transmission of CWD to small ruminants.
In closing, primary passage bioassay into Tg338 (ovine PRNP) and TgElk (elk PRNP) mice produced unique transmission profiles for the isolates of CWD and scrapie prions used in this study. These transmission observations also mimicked previous research experiences of limited interspecies transmission in the natural host species. The data suggest that these two transgenic mouse models may prove to be generally robust for detecting instances of interspecies transmission of CWD to small ruminants. Additional testing of other prion isolates and characterized strains may help further establish a discriminatory mouse model using Tg338 and TgElk. Furthermore, future studies on the subpassage of the homogenates described here may help determine the potential for phenotype adaptation of CWD prions in small ruminants and aid in further strain characterization.
Transgenic mice and goats or sheep with naturally acquired scrapie described in this study were maintained and procedures performed in accordance with use approved by Washington State University and University of Washington Institutional Animal Care and Use Committees. Breeding pairs of ovinized mice (strain Tg338; PrPC with the 136V, 154R, 171Q allele) (Laude et al., 2002; Vilotte et al., 2001) were kindly provided by Dr Hubert Laude (Institut National de la Recherche Agronomique, France) and held initially in a breeding colony at the University of Washington and subsequently in a breeding colony at Washington State University. Breeding pairs of cervidized mice (strain TgElk; PrPC with the 132M allele) (LaFauci et al., 2006) were kindly provided by Dr Robert Rowher (Research Foundation for Mental Hygiene, Inc.; Menands, NY, USA) and held in a breeding colony at Washington State University. Both lines are homozygous for the transgene with Tg338 expressing PrPC VRQ at 8–12-fold that of sheep brain (Douet et al., 2014; Laude et al., 2002), whereas TgElk express PrPC 132M at 2.5-fold relative to conventional mouse (LaFauci et al., 2006). Presence of the transgene was confirmed by DNA sequence analysis of tail snips and/or ear punches.
Sheep (S3178) and goats (G3538, G3558, G3953 and G30-75) with naturally acquired scrapie were referred by USDA Animal and Plant Health Inspection Service (APHIS) and are described in detail elsewhere (O'Rourke et al., 2011, 2012). WTD with naturally acquired CWD were identified during CWD surveillance and tissues collected by the Nebraska Game and Parks Commission as detailed in a previous study (O'Rourke et al., 2004).
The generation of sheep-passaged-CWD was conducted at the Canadian Food Inspection Agency, Ottawa Laboratory Fallowfield in accordance with Canadian Council on Animal Care guidelines under a protocol approved and monitored by the local Animal Care Committee. Under general anaesthesia, two 8-month-old ewes (CFIA113 and CFIA122) were intracerebrally inoculated with 1ml of a 10% (w/v in sterile normal saline) homogenate pooled from the brain and lymphoid tissues of 12 elks with CWD (CFIA Elk; all wild-type PRNP 132MM). Following a 1 cm skin incision, a 1 mm hole was trephined through the calvarium near the midline intersection of the parietal and frontal bones. Using a 9 cm long, 22 gauge needle the inoculum was slowly injected while withdrawing the needle from the midbrain. Beginning around 27months post-inoculation (p.i.), both sheep began showing subtle clinical signs consistent with prion disease including ataxia, teeth grinding and progressive recumbency. At 28months p.i. within 10 days of each other, both sheep were euthanized by barbiturate overdose and brain material was confirmed positive for pathological PrP by commercial ELISA (Bio-Rad TeSeE ELISA), WB and immunohistochemistry using methods previously described (Balachandran et al., 2010; Mitchell et al., 2015).
All inocula for mouse bioassay were prepared as previously described (O'Rourke et al., 2012). Briefly, brain tissues were prepared as 10% (w/v) homogenates in normal saline and assessed for bacterial contamination prior to the addition of gentamycin at a final concentration of 100µg ml−1. Homogenates that remained positive for bacterial growth after gentamycin treatment were heat treated (80°C for 15min, 37°C for 60min and 80°C for 15min) and reassessed for bacterial contamination. Inoculations were only performed with homogenates cleared of bacterial contamination. PrPSc and PrPCWD levels were assessed in all homogenates by EIA (HerdChek® CWD Ag Test; IDEXX Laboratories). Intracerebral inoculations were performed as described by O’Rourke et al. (2012). Mice were monitored and assessed for the appearance of clinical signs consistent with TSE disease (e.g. weight loss, lethargy and kyphosis). Mice were culled at clinical disease (clinical signs observed in two consecutive weeks or two out of three consecutive weeks) or within a predetermined endpoint period to limit losses due to intercurrent health issues (Bruce et al., 2004). Brain was collected at euthanasia and frozen at −20°C.
Survival time following intracerebral inoculation was defined as the number of days p.i. to the time of sacrifice due to clinical signs consistent with TSE disease in transgenic mice (Bruce et al., 2004; Di Bari et al., 2012). Recipient mice terminated for reasons other than clinical disease (intercurrent health issues or predetermined endpoint) were considered censored data. Mice removed from the study due to unforeseen circumstances (death within 1week of inoculation, cannibalization by cage mate, cannibalization of a cage mate more than 30days prior to cull or a facility issue) were not included in the calculation of survival times or shown in the graphs. The survival function of each inoculum was determined using the Kaplan–Meier product limit estimation method (LIFETEST procedure, SAS for Windows version 9.3; SAS Institute Inc.). Median survival times with 95% confidence limits were determined by the log (−log) method.
Detection of PrPres by WB was performed as previously described (O'Rourke et al., 2011, 2012). Briefly, 10% brain homogenates in PBS were diluted by adding an equal volume of 2× lysis buffer (20mM Tris-HCl pH 7.5; 1% NP-40, 1% sodium deoxycholate) and incubated with proteinase K (PK). Goat, sheep, WTD and TgElk brain homogenates were incubated with 50µg ml−1 PK, whereas Tg338 brain homogenates were incubated with 100 µg ml−1 PK for 60min at 37°C. Sample loading buffer (2× NuPAGE LDS Sample Buffer, Invitrogen) was added prior to electrophoresis through 12% Bis-Tris protein gels (Invitrogen) followed by transfer of proteins to PVDF membranes. Membranes were blocked with Blocker Casein (Pierce/Thermo Scientific) prior to incubation with the anti-prion antibody F99/97.6.1 (3.5µg ml−1) (O'Rourke et al., 2000) and HRP-conjugated goat anti-mouse IgG1 (1:5000; Southern Biotechnology). Chemiluminescent signal of bound antibody (Amersham ECL; GE Healthcare) was captured on film (Carestream Health BioMax™ Light Film; Fisher Scientific).
Mouse brain homogenates negative by direct lysis WB were further tested by PTA-enriched WB analysis (Spraker et al., 2004; Wadsworth et al., 2001). Briefly, brain homogenate was mixed 1:1 with 4% (w/v) Sarkosyl and incubated at 37°C for 15min followed by treatment with 100 µg ml−1 DNase at 37°C for 45min. Samples were centrifuged at ~1300g for 5min prior to treatment of supernatants with 100 µg ml−1 PK at 37°C for 60min. Sodium-PTA (4% w/v Na-PTA in 170mM MgCl2, pH 7.4) was added to yield a final concentration of 0.3% Na-PTA. Following incubation at 37°C for 60min, precipitated PrPres was pelleted by centrifugation (~20500 g for 30min) and the final pellet dissolved in ultrapure water prior to the addition of sample loading buffer, electrophoresis, protein transfer to PVDF membrane and detection as described above.
For molecular mass and glycoform analyses of PrPres in homogenate samples, WB films were scanned and saved in tiff file format with an image analyser (Alpha Innotech). Relative molecular mass of di-, mono- and unglycosylated PrPres was estimated based on migration of a protein standard (MagicMark™ XP Western Protein Standard; Invitrogen) included on each blot. Statistical analyses were performed on the molecular mass of unglycosylated PrPres of three or four replicate measurements for goat, sheep, deer and elk homogenate samples. The fixed effect of prion disease type was analysed using a general linear mixed model (PROC GLIMMIX; SAS 9.3; SAS Institute Inc.). Prion disease types that were considered included WTD with naturally acquired CWD, elk with naturally acquired CWD, sheep with naturally acquired scrapie, goats with naturally acquired scrapie, and sheep with experimental CWD derived from elk (sheep-passaged-CWD). The model included a random effects term for WB as each blot did not include all homogenates. Post-hoc comparison of fixed effect levels was by least squares means using stepdown Bonferroni adjustments; these options correspond to the methods of Holm (1979) for conducting sequentially rejective multiple comparisons. In addition, the Kenward and Roger option (kr) was selected for computing denominator degrees of freedom for tests of the fixed main effect and post-hoc comparisons. Holm-adjusted P values (P) were considered significant when <0.05.
Densities of di-, mono- and unglycosylated PrPres were estimated using AlphaEaseFC software (Alpha Innotech). The proportional composition of the three major PrPres bands is graphically presented on a three-axis plot generated using the ternary plot feature of JMP software (version 11; SAS Institute Inc.).
This study was supported by the USDA Agricultural Research Service under CRIS 2090-32000-030-00. We are grateful to L. Hamburg for mouse colony management and performing all mouse inoculations and necropsies. We are appreciative for the day-to-day care of all mice provided by the WSU-CVM Animal Resource Unit. We are also thankful for the assistance of L. Fuller and the USDA-ARS-ADRU animal care staff for the care of sheep and goats; D. Lesiak for assistance with PRNP genotyping in all animals and L. O’Rourke for assistance in the laboratory. Mention of trade names or commercial products in this article is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the US Department of Agriculture.